PMID- 26880493
OWN - NLM
STAT- MEDLINE
DCOM- 20170105
LR  - 20221207
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Feb 16
TI  - Diagnosis of adults Xp11.2 translocation renal cell carcinoma by 
      immunohistochemistry and FISH assays: clinicopathological data from ethnic 
      Chinese population.
PG  - 21677
LID - 10.1038/srep21677 [doi]
LID - 21677
AB  - This study aimed to assess the utility of transcription factor E3 (TFE3) 
      break-apart fluorescence in situ hybridization (FISH) assay in diagnosis of 
      Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and to compare the 
      clinicopathological features between adult Xp11.2 RCC and non-Xp11.2 RCC. 76 
      pathologically suspected Xp11.2 RCCs were recruited from our institution. Both 
      TFE3 immunohistochemistry (IHC) and TFE3 FISH assay were performed for the entire 
      cohort. The progression-free survival (PFS) and overall survival (OS) curves were 
      estimated using the Kaplan-Meier method. FISH analysis confirmed 30 Xp11.2 RCCs, 
      including 28 cases with positive TFE3 immunostaining and 2 cases with negative 
      immunostaining. The false-positive and false-negative rates were 6.7% (2/30) and 
      4.3% (2/46), respectively, for TFE3 IHC compared with FISH assay. Xp11.2 RCC was 
      significantly associated with higher pathological stage and Fuhrman nuclear grade 
      compared with non-Xp11.2 RCC (P < 0.05). The median PFS and OS for TFE3 
      FISH-positive group were 13.0 months (95% CI, 8.4-17.6 months) and 50.0 months 
      (95% CI, 27.6-72.4 months), respectively, while the median PFS and OS had not 
      been reached for TFE3 FISH-negative group. In conclusion, TFE3 break-apart FISH 
      assay is a highly useful and standard diagnostic method for Xp11.2 RCC. Adult 
      Xp11.2 RCC is clinically aggressive and often presents at advanced stage with 
      poor prognosis.
FAU - Qu, Yuanyuan
AU  - Qu Y
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Gu, Chengyuan
AU  - Gu C
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Wang, Hongkai
AU  - Wang H
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Chang, Kun
AU  - Chang K
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Yang, Xiaoqun
AU  - Yang X
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      200032, China.
FAU - Zhou, Xiaoyan
AU  - Zhou X
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      200032, China.
FAU - Dai, Bo
AU  - Dai B
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Zhu, Yao
AU  - Zhu Y
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Shi, Guohai
AU  - Shi G
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Zhang, Hailiang
AU  - Zhang H
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
FAU - Ye, Dingwei
AU  - Ye D
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      200032, China.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160216
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (TFE3 protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Asian People
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/*analysis/genetics
MH  - Carcinoma, Renal Cell/*diagnosis/pathology
MH  - *Chromosomes, Human, X
MH  - Diagnostic Errors
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Survival Analysis
MH  - *Translocation, Genetic
MH  - Young Adult
PMC - PMC4754949
EDAT- 2016/02/18 06:00
MHDA- 2017/01/06 06:00
PMCR- 2016/02/16
CRDT- 2016/02/17 06:00
PHST- 2015/09/25 00:00 [received]
PHST- 2015/12/30 00:00 [accepted]
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/01/06 06:00 [medline]
PHST- 2016/02/16 00:00 [pmc-release]
AID - srep21677 [pii]
AID - 10.1038/srep21677 [doi]
PST - epublish
SO  - Sci Rep. 2016 Feb 16;6:21677. doi: 10.1038/srep21677.